SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date: Thursday, Fe ...

Drug Development and Clinical Trials - iBio's AI Drug Discovery Platform enables the rapid generation of antibody therapeutics characterized by high specificity and optimized developability [265]. - The company anticipates IBIO-600 will enter Phase 1a clinical trials in the first half of calendar 2026, marking a significant milestone [242]. - In preclinical studies, IBIO-610 demonstrated an 8.9% reduction in body weight and a 26% reduction in fat mass in a diet-induced obesity mouse model [251]. - The combination of IBIO-610 with semaglutide resulted in a 35.3% weight loss, compared to 27.8% with semaglutide alone [252]. - IBIO-610 exhibited a terminal half-life of approximately 33.2 days in non-human primates, with projected human half-life estimated between 47 to 100 days [254]. - The company is developing a bispecific antibody targeting both myostatin and Activin A, showing promise in enhancing muscle cell differentiation [256]. - IBIO-600 was observed to prevent lean mass loss when administered in combination with a GLP-1 receptor agonist in preclinical studies [258]. - Early preclinical results from an amylin receptor antibody program showed a ~60% reduction in acute food intake in a proof-of-concept study [264]. Financial Performance - The company reported a net loss of approximately $14.7 million for the six months ended December 31, 2025, with negative cash flows from operations of approximately $10.9 million [299]. - The company reported a net loss of $9.0 million, or $0.09 per share, for the three months ended December 31, 2025, compared to a net loss of approximately $4.4 million, or $0.48 per share, for the same period in 2024 [306]. - For the six months ended December 31, 2025, the company reported a net loss of $14.7 million, or $0.19 per share, compared to a net loss of approximately $8.4 million, or $0.94 per share, for the same period in 2024 [312]. - The accumulated deficit as of December 31, 2025, was approximately $346.9 million, up from approximately $322.2 million as of December 31, 2024 [318]. Cash and Assets - Total current assets as of December 31, 2025, were approximately $53.4 million, including approximately $28.7 million in cash and cash equivalents [299]. - As of December 31, 2025, the company's cash and cash equivalents, along with investments in debt securities, totaled approximately $52.7 million, sufficient to fund operations for at least 12 months [300]. - The company raised approximately $26 million in gross proceeds from a private placement involving the issuance of 1,408,481 shares of common stock and pre-funded warrants [293]. - The purchase price per share in the private placement was $2.35, with pre-funded warrants priced at $2.349 [292]. - Net cash provided by financing activities during the six months ended December 31, 2025, was approximately $55.5 million, primarily from a public offering that raised approximately $50 million [315]. Research and Development Expenses - Research and Development (R&D) expenses increased to $4.3 million for the three months ended December 31, 2025, up from $1.9 million in the same period of 2024, reflecting a rise of approximately 126% [303]. - General and Administrative (G&A) expenses rose to approximately $5.2 million for the three months ended December 31, 2025, compared to $2.7 million in the same period of 2024, an increase of approximately 93% [304]. - Total operating expenses for the three months ended December 31, 2025, were approximately $9.4 million, compared to approximately $4.6 million in the same period of fiscal year 2024 [305]. - The operating capital deficit for the six months ended December 31, 2025, was $10.9 million, compared to a $7.6 million deficit for the same period in 2024 [299]. Strategic Collaborations - The company has entered into a collaboration with AstralBio to develop novel antibodies for obesity and cardiometabolic diseases, granting an exclusive license for four targets [287]. - iBio's strategic approach includes pursuing selective collaborations and out-licensing opportunities to broaden the use of its AI Drug Discovery Platform [247]. - The company is exploring partnerships for its preclinical immune-oncology candidates and seeking opportunities for future collaborations using its AI Drug Discovery Platform [291]. Technology and Innovation - The proprietary StableHu technology has been trained using over 1 billion human antibodies to optimize antibody development [274]. - The EngageTx CD3-based T-cell engager panel aims to reduce cytokine release while maintaining potent tumor-killing activity [279]. - The ShieldTx platform integrates antibody masking technology to enhance safety and efficacy by activating antibodies only in diseased tissues [282].

Financing and Cash Position - iBio secured $26 million in PIPE financing to advance preclinical programs and extend cash runway into Q3 FY 2028[1][3][7] - iBio's cash, cash equivalents, and investments totaled $52.7 million as of December 31, 2025[7] Revenue and Expenses - The company reported no revenue for Q2 FY 2026, compared to $0.2 million in Q2 FY 2025[4][15] - R&D expenses increased to $4.3 million in Q2 FY 2026 from $1.9 million in Q2 FY 2025, a rise of approximately 126.3%[5][15] - General and Administrative expenses rose to $5.2 million in Q2 FY 2026 from $2.7 million in Q2 FY 2025, an increase of 92.6%[6][15] - Total operating expenses for Q2 FY 2026 were $9.4 million, compared to $4.6 million in Q2 FY 2025[15] - The net loss for Q2 FY 2026 was $8.99 million, compared to a net loss of $4.36 million in Q2 FY 2025[15] Research and Development - IBIO-610, a potential first-in-class Activin E antibody, shows a predicted human half-life of up to 100 days, supporting dosing as infrequently as twice per year[3][11] - IBIO-600 is on track to enter Phase 1a clinical trials in the first half of calendar year 2026[3][11] - The company presented new data at industry conferences, including findings on long-acting antibodies for obesity therapeutics[3][10]

Core Viewpoint - iBio, Inc. has secured $26 million in PIPE financing to advance its preclinical programs and extend its cash runway, while also reporting no revenue for the second quarter of fiscal year 2026, highlighting significant increases in R&D and G&A expenses [1][4][7]. Financial Results - The company reported no revenue for the three months ending December 31, 2025, compared to $0.2 million for the same period in 2024 [4]. - R&D expenses increased to $4.3 million for the three months ending December 31, 2025, from $1.9 million in the same period of 2024, reflecting a rise of approximately $2.4 million [4][6]. - General and Administrative expenses rose to approximately $5.2 million for the three months ending December 31, 2025, up from $2.7 million in the same period of 2024, an increase of $2.5 million primarily due to impairment of intangible assets [7]. Corporate Updates - iBio has advanced its preclinical pipeline programs, including IBIO-610 and IBIO-600, towards human clinical trials, with CMC development and toxicology studies initiated [2]. - The company presented new data on IBIO-610 at various industry conferences, indicating a predicted human half-life of up to 100 days, which supports potential dosing as infrequently as twice per year [5]. - The company aims to commence first human clinical trials for IBIO-610 in early calendar year 2027 and enter Phase 1a clinical trials for IBIO-600 in the first half of calendar year 2026 [5][6]. Cash Position - As of December 31, 2025, iBio held cash, cash equivalents, and investments in debt securities totaling $52.7 million, with the recent PIPE financing extending the cash runway into the third quarter of fiscal year 2028 [8].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for iBio, Inc. despite lower revenues, with actual results being crucial for stock price movement [1] Earnings Expectations - iBio is expected to report a quarterly loss of $0.08 per share, reflecting a year-over-year change of +83.3% [3] - Revenues are projected to be $0.1 million, down 50% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 3.45% higher in the last 30 days, indicating a reassessment by analysts [4] - A positive Earnings ESP of +27.27% suggests analysts have become more optimistic about iBio's earnings prospects [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - iBio currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, iBio was expected to post a loss of $0.07 per share but actually reported a loss of -$0.11, resulting in a surprise of -57.14% [13] - Over the past four quarters, iBio has only beaten consensus EPS estimates once [14] Industry Comparison - Bristol Myers Squibb is expected to report an EPS of $1.15 for the same quarter, indicating a year-over-year change of -31.1% [18] - Revenues for Bristol Myers are expected to be $12.25 billion, down 0.7% from the previous year [18] - The consensus EPS estimate for Bristol Myers has been revised down by 3.9% in the last 30 days, and it currently has an Earnings ESP of 0.00% [19][20]

Core Viewpoint - iBio, Inc. has announced a private placement financing expected to generate approximately $26 million in gross proceeds to advance its preclinical programs and extend its cash runway into 2028 [1][3]. Group 1: Financing Details - The private placement financing is led by Frazier Life Sciences and includes participation from existing healthcare-focused institutional investors [2]. - iBio is selling 11,061,738 shares of common stock at a purchase price of $2.35 per share, with the offering expected to close around January 13, 2026 [4]. - The financing will provide funds to support the development of preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and other pipeline assets [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance key development milestones in preclinical programs and to fund working capital requirements [3]. - The financing is expected to extend iBio's cash runway into calendar 2028, allowing for continued development of its biopharmaceutical pipeline [3]. Group 3: Company Overview - iBio, Inc. is a biotech company utilizing AI and advanced computational biology to develop biopharmaceuticals for various diseases, including cardiometabolic diseases and cancer [7]. - The company aims to transform drug discovery and accelerate development timelines through innovative drug discovery platforms [7].

Summary of iBio Conference Call Company Overview - **Company**: iBio - **Industry**: Biotechnology, specifically focusing on antibody discovery and therapeutics for obesity and cardiometabolic diseases [2][3] Core Points and Arguments Product Pipeline - iBio's lead program is **iBio-610**, a long-acting Activin E antibody, which is the first and only molecule of its kind [2] - Non-human primate pharmacokinetic (PK) data indicates a predicted half-life of up to **100 days** in humans, allowing for potential dosing twice a year [2] - Anticipated IND filing in Australia by the end of **2026**, with the first patient expected in **2027** [3] Unique Discovery Approach - iBio employs a combination of generative AI and wet lab biology to enhance antibody development, focusing on specific epitopes for targeted action [4][5] - The company utilizes a **single-shot multidimensional optimization** approach to create highly developable long-acting antibodies [6] Addressing Gaps in Current Treatments - Current GLP-1 treatments for obesity have limitations, including adverse effects like nausea and vomiting, which restrict weight loss to about **10%** in real-world scenarios [9] - iBio's Amylin molecule is designed to selectively target Amylin receptors without affecting calcitonin receptors, potentially offering a more effective alternative to GLP-1s [10] - Concerns about muscle loss and increased fracture risk associated with GLP-1 treatments highlight the need for alternatives that preserve muscle mass [11][13] Target Populations - iBio identifies **sarcopenic obesity** as a significant market, with approximately **10 million** individuals needing fat loss without muscle loss [17] - The company also sees potential in addressing cardiovascular disease and chronic kidney disease in obese populations, leveraging their bispecific molecules [18] Partnership Strategy - iBio is actively seeking partnerships with companies that have established credibility in the obesity space to co-develop their myostatin program [19][20] - The company believes that achieving regulatory milestones will enhance partnership discussions [20] Financial Position and Strategy - iBio recently raised **$100 million**, providing cash runway into the second quarter of **2027** [34] - The company is looking to offload legacy immuno-oncology assets to focus on cardiometabolic obesity programs [35] Upcoming Milestones - The most significant upcoming milestone is the entry of **IBIO-600** into the clinic, expected in the first half of **next year**, which will validate the company's platform [36][37] - The Activin E program is also highlighted as a unique asset, being the only antibody against Activin E in development [37][38] Additional Important Points - iBio emphasizes the importance of safety in early clinical trials, aiming to establish early signs of efficacy through imaging techniques [28] - The company is positioned to learn from other long-acting therapies in development, potentially accelerating their clinical timelines [30][31] This summary encapsulates the key points discussed during the iBio conference call, focusing on the company's innovative approach to treating obesity and its strategic plans for future development and partnerships.

Core Insights - iBio, Inc. will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Miami, highlighting its focus on advancing its next-generation obesity pipeline [1][2]. Company Overview - iBio is an AI-driven biotech company specializing in precision antibody therapies for cardiometabolic diseases, obesity, cancer, and other challenging conditions [4]. - The company utilizes proprietary 3D modeling and innovative drug discovery platforms to develop breakthrough antibody treatments aimed at significant unmet medical needs [4]. Key Events - Martin Brenner, CEO and Chief Scientific Officer of iBio, will engage in a fireside chat on December 4, 2025, discussing the promising non-human primate data for IBIO-610, a potential first-in-class Activin E antibody [2]. - Felipe Duran, CFO of iBio, will be available for one-on-one meetings during the conference, providing opportunities for direct engagement with investors [3]. Additional Information - A livestream of the conference will be available, and a replay will be posted on the Investor section of the iBio website [3].

Core Insights - iBio, Inc. reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -57.14% [1] - The company generated revenues of $0.1 million for the quarter ended September 2025, consistent with the Zacks Consensus Estimate, compared to zero revenues a year ago [2] - iBio shares have declined approximately 49.4% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] Company Performance - Over the last four quarters, iBio has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $0.1 million, and for the current fiscal year, it is -$0.40 on revenues of $0.5 million [7] - The estimate revisions trend for iBio was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which iBio belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Product Development - iBio's preclinical product candidate pipeline includes IBIO-610, which demonstrated an 8.9% reduction in body weight and a 26% reduction in fat mass in a diet-induced obesity mouse model [236]. - The combination therapy of IBIO-610 with semaglutide resulted in a 35.3% weight loss, compared to a 27.8% reduction with semaglutide alone [237]. - IBIO-610 exhibited a terminal half-life of approximately 33.2 days in non-human primates, with a projected human half-life estimated between 47 to 100 days [239]. - The bispecific antibody targeting myostatin and Activin A is in late discovery, optimizing parameters such as binding affinity and stability [241]. - IBIO-600, a long-acting anti-myostatin antibody, showed a half-life of approximately 40 to 52 days in non-human primates, with a projected human half-life of 57 to 147 days [245]. - Early preclinical results for an amylin receptor antibody showed a ~60% reduction in acute food intake in a proof-of-concept study [249]. - iBio's AI Drug Discovery Platform enables rapid generation of antibody therapeutics characterized by high specificity and optimized developability [250]. - The platform integrates epitope engineering, a proprietary antibody library, and antibody optimization technologies to enhance the probability of success in drug development [251]. - The company has a pipeline of pre-clinical programs, including IBIO-600 and IBIO-610, focusing on obesity and cardiometabolic diseases, with ongoing efforts to seek partnerships for these programs [270]. Financial Performance - For the three months ended September 30, 2025, the company incurred a net loss of approximately $5.7 million, or $0.11 per share, compared to a net loss of approximately $4.0 million, or $0.46 per share for the same period in 2024 [287]. - Research and Development (R&D) expenses increased to $3.6 million for the three months ended September 30, 2025, up from $1.3 million in the same period of 2024, reflecting a rise of approximately 176% [284]. - General and Administrative (G&A) expenses decreased to approximately $2.5 million for the three months ended September 30, 2025, down from $2.8 million in the same period of 2024, a reduction of approximately 11% [285]. - Total operating expenses for the three months ended September 30, 2025, were approximately $6.1 million, compared to approximately $4.1 million in the same period of 2024, indicating an increase of approximately 49% [286]. - The company recognized revenue of $0.1 million for services provided to a collaborative partner during the three months ended September 30, 2025, while no revenue was recognized in the same period of 2024 [283]. Cash Position and Liquidity - As of September 30, 2025, the company had total current assets of approximately $50.8 million, including approximately $28.1 million in cash and cash equivalents [278]. - The company raised gross proceeds of approximately $50 million from an underwritten public offering in August 2025, with net proceeds of approximately $46.5 million after deducting underwriting discounts and commissions [276]. - The company’s current cash position is believed to be sufficient to fund operations for at least 12 months from the date of filing the Quarterly Report [279]. - The company’s liquidity position is challenged by a history of significant losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern [280]. - Net cash used in operating activities was approximately $5.7 million for the three months ended September 30, 2025, compared to $3.7 million for the same period in 2024, primarily due to funding net losses [288]. - Net cash used in investing activities was approximately $21.5 million for the three months ended September 30, 2025, attributed to the purchase of debt securities and fixed assets, while it was $0.7 million for the same period in 2024 [289]. - Net cash provided by financing activities was approximately $46.7 million for the three months ended September 30, 2025, from the sale of securities, offset by debt payments, compared to $0.2 million used in financing activities in 2024 [290]. - As of September 30, 2025, the accumulated deficit was approximately $337.9 million, increasing from $317.8 million as of September 30, 2024 [292]. - Current cash, cash equivalents, and investments in debt securities were approximately $49.6 million as of September 30, 2025, expected to support operations into the fourth quarter of fiscal year 2027 [292]. Future Outlook and Risks - The company plans to fund future operations through cash on hand, commercialization proceeds, and potential asset sales or collaborations, but there is no assurance of success [293]. - The company may need to adjust cash flow projections and valuation assumptions due to competitive pressures and rising interest rates, which could lead to future impairments [304]. - No triggering events for impairment were identified during the three months ended September 30, 2025, but the company will continue to monitor the value of its intangible assets [303]. - The company does not participate in off-balance sheet arrangements or transactions with unconsolidated entities as of September 30, 2025 [294]. - The company anticipates commencing its first human clinical trials for IBIO-610 in early 2027 [228].